Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma
All participants must be enrolled on protocol, "Collection of Specimens and Clinical Data
from Patients with Renal Cell Carcinoma Treatment with Targeted Therapies", about to start a
treatment course with sunitinib and AMG386, and willing to come in for successive MRIs at
the following times: baseline, 2 weeks upon initiation of therapy with sunitinib and AMG386,
after cycle 2 and/or cycle 4 of therapy, and at the end of your study therapy.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To explore the association of baseline blood flow in renal cell carcinoma(RCC) measured by ASL MRI and tumor response to treatment with the combination of sunitinib and AMG386
2 years
No
Ivan Pedrosa, MD
Principal Investigator
Beth Israel Deaconess Medical Center
United States: Institutional Review Board
09-105
NCT00953446
August 2009
Name | Location |
---|---|
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |